Dogwood Therapeutics, Inc. (DWTX)
NASDAQ: DWTX · Real-Time Price · USD
4.250
+0.070 (1.67%)
At close: Apr 4, 2025, 4:00 PM
4.240
-0.010 (-0.24%)
After-hours: Apr 4, 2025, 7:52 PM EDT

Company Description

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response.

The company’s lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.

It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID.

The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024.

The company was founded in 2012 and is headquartered in Alpharetta, Georgia.

Dogwood Therapeutics, Inc.
Dogwood Therapeutics logo
Country United States
Founded 2012
Industry Biotechnology
Sector Healthcare
Employees 4
CEO Gregory Duncan

Contact Details

Address:
44 Milton Avenue
Alpharetta, Georgia 30009
United States
Phone 866 620 8655
Website dwtx.com

Stock Details

Ticker Symbol DWTX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001818844
ISIN Number US92829J2033
Employer ID 85-4314201
SIC Code 2834

Key Executives

Name Position
Gregory Duncan Chairman and Chief Executive Officer
Dr. William L. Pridgen M.D. Founder and Member of Scientific Advisory Board
Angela Walsh Chief Financial Officer, Secretary and Treasurer
Dr. R. Michael Gendreau M.D., Ph.D. Chief Medical Officer
Ralph D. Grosswald M.P.H. Senior Vice President of Operations
Carol Duffy Ph.D. Chief Scientific Advisor

Latest SEC Filings

Date Type Title
Apr 3, 2025 8-K Current Report
Mar 31, 2025 10-K Annual Report
Mar 31, 2025 8-K Current Report
Mar 17, 2025 SCHEDULE 13D/A Filing
Mar 17, 2025 SCHEDULE 13G/A Filing
Mar 17, 2025 SCHEDULE 13G Filing
Mar 14, 2025 8-K Current Report
Mar 14, 2025 424B5 Filing
Mar 12, 2025 8-K Current Report
Dec 18, 2024 8-K/A [Amend] Current report